Want to see AU:BIO full AI Analyst Report?
BIO Stock Chart & Stats
AU$0.26
AU$0.02(5.88%)
At close: 4:00 PM EDT
AU$0.26
AU$0.02(5.88%)
Day’s Range― - ―
52-Week RangeAU$0.20 - AU$0.57
Previous CloseN/A
Volume215.99K
Average Volume (3M)278.69K
Market Cap
AU$68.40M
Enterprise ValueAU$94.12
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)64.0
Beta1.05
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.04
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.03
Revenue Forecast (FY)AU$36.50M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line expansion indicates growing market adoption of Biome's probiotic products and distribution reach. Durable revenue growth supports reinvestment in product development and marketing, helps absorb fixed costs, and underpins longer-term scale economics across channels.
High Gross MarginA ~61% gross margin signals strong unit economics and pricing power for Biome's formulations. Such structural margin advantage provides room to fund marketing, R&D and channel expansion while preserving profitability if input costs rise, supporting margin sustainability.
Balance Sheet StrengthModerate leverage with a manageable D/E and positive ROE indicates a stable capital structure and ability to finance growth without excessive risk. A strong equity ratio offers a buffer for investments or downturns and preserves strategic flexibility over the medium term.
Bears Say
Operating Cash Flow WeaknessNegative operating cash flow despite reported growth points to weak cash conversion from core operations, likely from working capital or receivables. This structural cash shortfall limits self‑funding ability, increasing reliance on external financing for sustained growth or capex.
Thin Net ProfitabilityVery low net margins mean most revenue is absorbed by operating costs and overhead, leaving little cushion for shocks. Persistently thin profitability constrains reinvestment, reduces free cash flow resilience, and makes the business sensitive to cost inflation or pricing pressure.
Mixed Quality Of EarningsManagement's reported growth and margins do not yet consistently convert to cash, suggesting potential non‑recurring items or timing differences. This structural earnings quality issue raises the risk of future volatility and undermines confidence in sustainable profit generation.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.20 and its highest was AU$0.57 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$68.40M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Sep 01, 2026 which is in 32 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 227,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (188.46% Upside)
AU$0.75 (188.46% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$146.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited, founded in 2018 and headquartered in Cremorne, Australia, specializes in the development, commercialization, and global distribution of live biotherapeutic and complementary health products. The company's product line features live biotherapeutics under the Activated Probiotics brand, organic nutritional supplements branded as Activated Nutrients, and athletic performance and recovery items named Activated X Performance. These offerings are accessible to consumers through both community pharmacies and independent health practitioners.
BIO Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(188.46% Upside)
Technical Analysis
Immuron Limited
―
Avecho Biotechnology Limited
―
Anatara Lifesciences Ltd
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―